WebbSubstrates and inhibitors of BCRP include a wide range of clinically important and structurally diverse drugs (e.g. rosuvastatin, glyburide, nitrofurantoin, dipyridamole, cimetidine, chlorothiazide, sulfasalazine, … WebbBCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML). Blood 108, 163a (2006). 74. Carter, T. A. et al. Inhibition of drug-resistant mutants

Table of Substrates, Inhibitors and Inducers

Webb21 aug. 2015 · Until now several efforts have been taken to identify potent and selective inhibitors of ABCG2. Recent studies carried out to deign BCRP inhibitors have been … Webb7 juli 2016 · Several reviews have provided exhaustive lists of compounds that are known BCRP substrates and/or inhibitors based on in vitro data (eg, efflux ratio, K m, K i, IC 50). 1, 6, 13 Rosuvastatin, pitavastatin, and sulfasalazine are proposed in vivo BCRP probe substrates. 1, 6, 13 Contrasting recommendations exist, as some do not recommend … monitor apache hbase

Use of P-glycoprotein and BCRP inhibitors to improve oral ...

Webb31 dec. 2013 · Due to the binding competition, some substrates for BCRP/ABCG2 have also been recognized as inhibitors of BCRP/ABCG2 when other BCRP/ABCG2 substrates were used simultaneously. Therefore, co-treatment with other anti-cancer drugs, which were also defined as BCRP/ABCG2 substrate, may be an alternative way to … Webb2 juli 2014 · Testing for substrates and inhibitors of BCRP using VT assays is of particular importance as BCRP is known to have many low passive permeable substrates and inhibitors (Poirier et al., 2014),... WebbFlavonoids and their derivatives such as 5, 7-dihydroflavone and biochanin A are the most potent inhibitors. The activated cysteine residues can also be used as inhibitors. … monitor apache